Trick and treat: Ambushing recurrent tumors before they get out of the door

Nicolas Boisgerault, Richard G. Vile

Research output: Contribution to journalArticle


Monitoring and treating dormant tumors represents a major clinical challenge. We have recently found that early recurring tumors elicit an innate immune response that can be detected systemically. We also demonstrated that it may be possible to target minimal residual disease before or after immune evasion with carefully timed, rational therapeutic approaches.

Original languageEnglish (US)
Article numbere27811
Issue number1
StatePublished - Jan 1 2014



  • Innate immune response
  • Minimum residual disease
  • Tumor dormancy
  • Tumor recurrence
  • VEGF

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this